Polyphor, a clinical stage biopharmaceutical company, focuses on the development of new antibiotics against Gram-negative bacteria with its Outer Membrane Protein Targeting Antibiotic (OMPTA) platform. Polyphor is also developing an immuno-oncology candidate to improve therapy outcomes in cancer.

Products, services, technology

Murepavadin:  Outer Membrane Protein Targeting Antibiotic against Pseudomonas aeruginosa in Phase III,
Balixafortide: Antagonist of CXCR4 in Phase III for breast cancer,
POL6014 – Outlicensed to Santhera: Inhaled inhibitor of neutrophil elastase for treatment of severe lung diseases

Location
Facts & figures
  • Type of organization
    Public company
  • Year of foundation
    1996
  • Number of employees in Switzerland
    50-149
Key business